Drug-induced psychosis in Parkinson disease - Phenomenology and correlations among psychosis rating instruments

被引:54
作者
Chou, KL
Messing, S
Oakes, D
Feldman, PD
Breier, A
Friedman, JH
机构
[1] Brown Univ, Sch Med, Dept Clin Neurosci, Providence, RI 02912 USA
[2] Univ Rochester, Dept Biostat, Rochester, NY USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
psychosis; hallucinations; delusions; Parkinson disease; rating scales;
D O I
10.1097/01.wnf.0000180228.77802.32
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with the Clinical Global Impression Scale (CGIS). Methods: Baseline data from two placebo-controlled, double-blind studies of olanzapine in PD patients with DIP were collected and analyzed. Results: A total of 157 of 160 patients had hallucinations, with visual hallucinations being the most common (97% of subjects), followed by auditory (48%), tactile (23%), and olfactory (16%). Seventy-six percent of subjects experienced delusions, and all types of delusions occurred with relatively equal frequency. The CGIS correlated with suspiciousness, hallucinatory behavior, unusual thought content, and hostility on the BPRS; and delusions, hallucinations, agitation, aberrant motor behavior, and sleep on the NPI. Conclusion: Nonvisual hallucinations and delusions may occur more frequently in DIP than previously thought. These symptoms, plus agitation and hostility, may ultimately be the best measure of DIP in patients with PD.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 19 条
  • [1] Prevalence and clinical correlates of psychotic symptoms in Parkinson disease - A community-based study
    Aarsland, D
    Larsen, JP
    Cummings, JL
    Laake, K
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (05) : 595 - 601
  • [2] Visual hallucinations in Parkinson's disease: a review and phenomenological survey
    Barnes, J
    David, AS
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 70 (06) : 727 - 733
  • [3] Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease
    Breier, A
    Sutton, VK
    Feldman, PD
    Kadam, DL
    Ferchland, I
    Wright, P
    Friedman, JH
    [J]. BIOLOGICAL PSYCHIATRY, 2002, 52 (05) : 438 - 445
  • [4] PSYCHOSIS AND OTHER PSYCHIATRIC MANIFESTATIONS OF LEVODOPA THERAPY
    CELESIA, GG
    BARR, AN
    [J]. ARCHIVES OF NEUROLOGY, 1970, 23 (03) : 193 - &
  • [5] CHACKO RC, 1995, J NEUROPSYCH CLIN N, V7, P471
  • [6] THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA
    CUMMINGS, JL
    MEGA, M
    GRAY, K
    ROSENBERGTHOMPSON, S
    CARUSI, DA
    GORNBEIN, J
    [J]. NEUROLOGY, 1994, 44 (12) : 2308 - 2314
  • [7] Factor S A, 1995, Adv Neurol, V65, P115
  • [8] Hallucinations in Parkinson's disease -: Prevalence, phenomenology and risk factors
    Fénelon, G
    Mahieux, F
    Huon, R
    Ziégler, M
    [J]. BRAIN, 2000, 123 : 733 - 745
  • [9] Friedberg G, 1998, CLIN NEUROPHARMACOL, V21, P280
  • [10] Sleep and fatigue in Parkinson's disease
    Friedman, JH
    Chou, KL
    [J]. PARKINSONISM & RELATED DISORDERS, 2004, 10 : S27 - S35